RxDoctor Payments Data

Susan Newman, MD

Family Medicine · Grand Island, NENPI 1396056396

Payments from drug & device makers

$418in general payments, 2019–2025

Across 23 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$102
  • AbbVie$100
  • Pfizer$59
  • Abbott$56
  • Dexcom, Inc.$26
  • GSK$24
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.5$102
AbbVie(2 entities)4$100
Pfizer4$59
Abbott3$56
Dexcom, Inc.2$26
GSK2$24
Merck1$23
Ironshore Pharmaceuticals Inc.1$14
Lilly USA, LLC1$13

How this compares

$418 in reported general payments places this provider in the 45th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$102,225
Medicare patients
184
Services billed
3,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$54,332
OzempicSemaglutide40$42,119
JardianceEmpagliflozin51$38,052
JanuviaSitagliptin Phosphate41$37,590
FarxigaDapagliflozin Propanediol44$33,423
XareltoRivaroxaban30$26,798
ArexvyRsvpref3 Antigen/As01e/Pf48$14,502
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$13,653
AbrysvoRsv Vacc, Pref A And Pref B/Pf38$12,167
ShingrixVaricella-Zoster Ge/As01b/Pf54$11,876
LinzessLinaclotide20$11,333
EliquisApixaban12$10,598
Fiasp FlextouchInsulin Aspart (Niacinamide)17$10,588
Breo ElliptaFluticasone/Vilanterol20$8,970
Atorvastatin Calcium351$3,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$13$54,33244 claims
MerckJanuvia$23$37,59041 claims
GSKArexvy, Shingrix, Breo Ellipta$24$35,347122 claims
PfizerAbrysvo, Eliquis$59$22,76550 claims
AbbVieLinzess, Synthroid$100$12,53646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →